Objective: To determine the clinical application value of Huaxian decoction by observing its clinical efficacy in treatment of hepatic fibrosis. Method: The 60 patients with hepatic fibrosis in gastroenterology and hepatology clinic and inpatient department of our hospital from January 2012 to December 2015 were included in the present study

and randomly divided into treatment group (30 cases) and control group (30 cases). Patients in treatment group received Huaxian decoction

and patients in control group received Silybin. Both groups were observed for clinical efficacy

and the changes in liver function

instantaneous elastic indexes in liver

hepatic fibrosis indexes

liver B-ultrasound

computed tomography (CT) or magnetic resonance imaging (MRI) and other objective indexes. Result: As compared with the conditions before treatment

the laboratory parameters such as transaminases

instantaneous elastic index in the liver

and hepatic fibrosis indexes were significantly reduced in both groups (P<0.05). The efficacy in treatment group was superior to that of control group after treatment (P<0.05). Conclusion: Huaxian decoction has certain effect in treatment of hepatic fibrosis

and further more multi-center and multi-link studies are required.